Literature DB >> 19053783

Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.

Constantinos Baskakis1, Victoria Magrioti, Naomi Cotton, Daren Stephens, Violetta Constantinou-Kokotou, Edward A Dennis, George Kokotos.   

Abstract

The development of selective inhibitors for individual PLA(2) enzymes is necessary in order to target PLA(2)-specific signaling pathways, but it is challenging due to the observed promiscuity of known PLA(2) inhibitors. In the current work, we present the development and application of a variety of synthetic routes to produce pentafluoro, tetrafluoro, and trifluoro derivatives of activated carbonyl groups in order to screen for selective inhibitors and characterize the chemical properties that can lead to selective inhibition. Our results demonstrate that the pentafluoroethyl ketone functionality favors selective inhibition of the GVIA iPLA(2), a very important enzyme for which specific, potent, reversible inhibitors are needed. We find that 1,1,1,2,2-pentafluoro-7-phenyl-heptan-3-one (FKGK11) is a selective inhibitor of GVIA iPLA(2) (X(I)(50) = 0.0073). Furthermore, we conclude that the introduction of an additional fluorine atom at the alpha' position of a trifluoromethyl ketone constitutes an important strategy for the development of new potent GVIA iPLA(2) inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053783      PMCID: PMC2649009          DOI: 10.1021/jm800649q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  47 in total

Review 1.  Group V sPLA2: classical and novel functions.

Authors:  Barbara Balestrieri; Jonathan P Arm
Journal:  Biochim Biophys Acta       Date:  2006-07-28

2.  Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2.

Authors:  David A Six; Efrosini Barbayianni; Vassilios Loukas; Violetta Constantinou-Kokotou; Dimitra Hadjipavlou-Litina; Daren Stephens; Alan C Wong; Victoria Magrioti; Panagiota Moutevelis-Minakakis; Sharon F Baker; Edward A Dennis; George Kokotos
Journal:  J Med Chem       Date:  2007-08-02       Impact factor: 7.446

3.  Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2alpha.

Authors:  Joachim Ludwig; Stefanie Bovens; Carsten Brauch; Alwine Schulze Elfringhoff; Matthias Lehr
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

Review 4.  Inhibitors of secretory phospholipase A2 group IIA.

Authors:  Robert C Reid
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

5.  Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease.

Authors:  Athena Kalyvas; Samuel David
Journal:  Neuron       Date:  2004-02-05       Impact factor: 17.173

6.  Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption.

Authors:  Yoshiyuki Satake; Bruno L Diaz; Barbara Balestrieri; Bing K Lam; Yoshihide Kanaoka; Michael J Grusby; Jonathan P Arm
Journal:  J Biol Chem       Date:  2004-02-04       Impact factor: 5.157

7.  Novel trifluoromethyl ketones as potent gastric lipase inhibitors.

Authors:  George Kokotos; Stavroula Kotsovolou; Robert Verger
Journal:  Chembiochem       Date:  2003-01-03       Impact factor: 3.164

8.  Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury.

Authors:  Rubèn López-Vales; Xavier Navarro; Takao Shimizu; Constantinos Baskakis; George Kokotos; Violetta Constantinou-Kokotou; Daren Stephens; Edward A Dennis; Samuel David
Journal:  Brain       Date:  2008-08-21       Impact factor: 13.501

9.  Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages.

Authors:  J Balsinde; E A Dennis
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

Review 10.  Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2.

Authors:  Christina C Leslie
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2004-04       Impact factor: 4.006

View more
  23 in total

1.  Electrophotocatalytic diamination of vicinal C-H bonds.

Authors:  Tao Shen; Tristan H Lambert
Journal:  Science       Date:  2021-02-04       Impact factor: 47.728

Review 2.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

3.  Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.

Authors:  Varnavas D Mouchlis; Dimitris Limnios; Maroula G Kokotou; Efrosini Barbayianni; George Kokotos; J Andrew McCammon; Edward A Dennis
Journal:  J Med Chem       Date:  2016-04-28       Impact factor: 7.446

4.  Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2.

Authors:  Varnavas D Mouchlis; Christophe Morisseau; Bruce D Hammock; Sheng Li; J Andrew McCammon; Edward A Dennis
Journal:  Bioorg Med Chem       Date:  2016-05-10       Impact factor: 3.641

5.  Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2.

Authors:  George Kokotos; Yuan-Hao Hsu; John E Burke; Constantinos Baskakis; Christoforos G Kokotos; Victoria Magrioti; Edward A Dennis
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

Review 6.  Chemical modulation of glycerolipid signaling and metabolic pathways.

Authors:  Sarah A Scott; Thomas P Mathews; Pavlina T Ivanova; Craig W Lindsley; H Alex Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-15

7.  Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Caryl Antalis; Zhanzhong Zhao; Robert Emerson; Gang Wei; Sheng Zhang; Zhong-Yin Zhang; Yan Xu
Journal:  Am J Pathol       Date:  2011-05-17       Impact factor: 4.307

8.  2-Oxoamide inhibitors of cytosolic group IVA phospholipase A2 with reduced lipophilicity.

Authors:  Georgia Antonopoulou; Victoria Magrioti; Maroula G Kokotou; Aikaterini Nikolaou; Efrosini Barbayianni; Varnavas D Mouchlis; Edward A Dennis; George Kokotos
Journal:  Bioorg Med Chem       Date:  2016-07-27       Impact factor: 3.641

9.  2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides.

Authors:  Efrosini Barbayianni; Daren Stephens; Andrej Grkovich; Victoria Magrioti; Yuan-Hao Hsu; Panagiotis Dolatzas; Dimitrios Kalogiannidis; Edward A Dennis; George Kokotos
Journal:  Bioorg Med Chem       Date:  2009-05-03       Impact factor: 3.641

10.  Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.

Authors:  Athena Kalyvas; Constantinos Baskakis; Victoria Magrioti; Violetta Constantinou-Kokotou; Daren Stephens; Rubèn López-Vales; Jian-Qiang Lu; V Wee Yong; Edward A Dennis; George Kokotos; Samuel David
Journal:  Brain       Date:  2009-02-13       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.